Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NYSE:BHVN NASDAQ:IMCR NASDAQ:IRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$26.83-1.4%$29.83$22.24▼$46.00$1.59B0.581.03 million shs196,518 shsBHVNBiohaven$9.71-0.1%$9.88$7.48▼$22.05$1.46B1.322.41 million shs587,049 shsIMCRImmunocore$30.79+6.7%$30.98$27.44▼$40.71$1.56B0.74430,159 shs82,951 shsIRDOpus Genetics$5.25+1.0%$4.81$0.90▼$5.81$375.92M0.62888,302 shs215,525 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-3.37%+9.72%-22.70%-1.77%-9.21%BHVNBiohaven+0.80%+1.08%-0.88%-11.59%-57.03%IMCRImmunocore+2.41%+0.17%-6.45%-8.44%-5.84%IRDOpus Genetics+1.17%+4.00%+14.29%+127.07%+448.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$26.83-1.4%$29.83$22.24▼$46.00$1.59B0.581.03 million shs196,518 shsBHVNBiohaven$9.71-0.1%$9.88$7.48▼$22.05$1.46B1.322.41 million shs587,049 shsIMCRImmunocore$30.79+6.7%$30.98$27.44▼$40.71$1.56B0.74430,159 shs82,951 shsIRDOpus Genetics$5.25+1.0%$4.81$0.90▼$5.81$375.92M0.62888,302 shs215,525 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-3.37%+9.72%-22.70%-1.77%-9.21%BHVNBiohaven+0.80%+1.08%-0.88%-11.59%-57.03%IMCRImmunocore+2.41%+0.17%-6.45%-8.44%-5.84%IRDOpus Genetics+1.17%+4.00%+14.29%+127.07%+448.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.5654.89% UpsideBHVNBiohaven 2.78Moderate Buy$22.47131.50% UpsideIMCRImmunocore 2.36Hold$60.8997.79% UpsideIRDOpus Genetics 2.85Moderate Buy$10.3096.19% UpsideCurrent Analyst Ratings BreakdownLatest IRD, AGIO, IMCR, and BHVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026BHVNBiohaven Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$23.00 ➝ $22.004/30/2026IRDOpus Genetics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/28/2026IRDOpus Genetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/28/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$12.004/27/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026IMCRImmunocore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026IRDOpus Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.004/20/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $50.004/20/2026IMCRImmunocore HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M29.53N/AN/A$18.65 per share1.44BHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/AIMCRImmunocore$400.02M3.90N/AN/A$7.52 per share4.09IRDOpus Genetics$14.20M26.40N/AN/A$0.22 per share23.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%N/ABHVNBiohaven-$738.82M-$6.96N/AN/AN/AN/A-1,146.34%-137.71%5/11/2026 (Estimated)IMCRImmunocore-$35.51M-$0.70N/AN/AN/A-8.88%-9.20%-3.32%5/6/2026 (Estimated)IRDOpus Genetics-$49.59M-$0.82N/AN/AN/A-349.33%-338.88%-85.82%5/21/2026 (Estimated)Latest IRD, AGIO, IMCR, and BHVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026IRDOpus Genetics-$0.16N/AN/AN/A$3.14 millionN/A5/11/2026Q1 2026BHVNBiohaven-$0.86-$0.69+$0.17-$0.88$0.27 millionN/A5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.03 million$106.68 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/2/2026Q4 2025BHVNBiohaven-$1.22-$1.21+$0.01-$1.21$3.86 millionN/A2/25/2026Q4 2025IMCRImmunocore-$0.28-$0.60-$0.32-$0.60$145.48 million$104.48 million2/14/2026Q4 2025IMCRImmunocoreN/A-$0.60N/A-$0.60N/A$104.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59BHVNBiohaven4.593.183.18IMCRImmunocore1.034.044.01IRDOpus GeneticsN/A6.436.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ABHVNBiohaven88.78%IMCRImmunocore84.50%IRDOpus Genetics14.97%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%BHVNBiohaven13.80%IMCRImmunocore10.40%IRDOpus Genetics11.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableBHVNBiohaven239150.42 million129.66 millionOptionableIMCRImmunocore32050.69 million45.42 millionOptionableIRDOpus Genetics1471.40 million63.05 millionN/AIRD, AGIO, IMCR, and BHVN HeadlinesRecent News About These CompaniesHere is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ StocksMay 5 at 3:00 PM | insidermonkey.comOpus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) ProgramMay 4 at 4:30 PM | globenewswire.comOpus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 4 at 4:17 AM | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Opus Genetics (IRD)May 2, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC)May 2, 2026 | theglobeandmail.comCitizens Initiates Coverage of Opus Genetics (IRD)May 1, 2026 | insidermonkey.comCitizens Initiates Coverage of Opus Genetics (IRD) with Market Outperform RecommendationApril 29, 2026 | msn.comOpus Genetics (NASDAQ:IRD) Now Covered by Analysts at Citizens JmpApril 28, 2026 | marketbeat.comJoseph Schachle Sells 4,697 Shares of Opus Genetics (NASDAQ:IRD) StockApril 28, 2026 | insidertrades.comOpus Genetics (NASDAQ:IRD) COO Sells $24,518.34 in StockApril 27, 2026 | marketbeat.comOpus Genetics (NASDAQ:IRD) President Benjamin Yerxa Sells 7,470 SharesApril 27, 2026 | marketbeat.comOpus Genetics (NASDAQ:IRD) Insider Ashwath Jayagopal Sells 7,542 SharesApril 27, 2026 | marketbeat.comOpus Genetics (NASDAQ:IRD) CFO Robert Gagnon Sells 7,842 SharesApril 27, 2026 | marketbeat.comOpus Genetics (NASDAQ:IRD) CEO Sells $49,647.42 in StockApril 27, 2026 | marketbeat.comOpus Genetics to Participate in Leading Medical Conferences in May 2026April 27, 2026 | globenewswire.comOpus Genetics Secures $155 Million Senior Note FinancingApril 24, 2026 | tipranks.comOpus Genetics Shareholders Approve Governance and Capital ChangesApril 22, 2026 | tipranks.comAnalysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), Argenx Se (ARGX)April 16, 2026 | theglobeandmail.comOpus Genetics Inc Ordinary Shares IRDApril 11, 2026 | morningstar.comMOpus Genetics Announces Data Presentations at the 2026 American Society of Cataract and ...April 10, 2026 | caledonianrecord.comCOpus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingApril 10, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Allbirds Exits Shoes, Pivots to AI With NewBird RebrandBy Leo Miller | April 21, 2026AST SpaceMobile Drops 15% After Blue Origin Satellite MishapBy Jessica Mitacek | April 22, 2026AST SpaceMobile Gets FCC Green Light for Direct-to-Device Service After Launch SetbackBy Jessica Mitacek | April 28, 2026IRD, AGIO, IMCR, and BHVN Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$26.83 -0.38 (-1.40%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Biohaven NYSE:BHVN$9.70 -0.01 (-0.05%) As of 11:37 AM Eastern This is a fair market value price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Immunocore NASDAQ:IMCR$30.78 +1.95 (+6.74%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Opus Genetics NASDAQ:IRD$5.25 +0.05 (+0.96%) As of 11:37 AM Eastern This is a fair market value price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
